Roche WB28183: A Phase III Randomized Double-Blind Placebo-Controlled Study to Assess The Efficacy Safety and Tolerability of Lebrikizumab in Adolescent Patients with Uncontrolled Asthma who are on inhaled corticosteroids and a second controller Medication
-
- STATUS
- Not Recruiting
Summary
The proposed clinical development program for lebrikizumab will evaluate whether specific modulation of a type 2 helper T cell (Th2) immune pathway that is mediated by interleukin-13 (IL-13) will improve clinical outcomes in patients with asthma whose disease remains uncontrolled by standard guideline-based therapies.
Description
The proposed clinical development program for lebrikizumab will evaluate whether specific modulation of a type 2 helper T cell (Th2) immune pathway that is mediated by interleukin-13 (IL-13) will improve clinical outcomes in patients with asthma whose disease remains uncontrolled by standard guideline-based therapies.
Details
| Condition | asthma |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX4567 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.